Evidence map›Paper›PMID 40790755›Full record

ArticleOrphanet journal of rare diseases2025

Patient experience in retinitis pigmentosa and Choroideremia- a concept elicitation study in 17 patients based on qualitative interviews.

Elke Rometsch, Per-Olof Thuresson, Noémie Hurst, Eckhart Eule, Isabel Bachmeier, Benoit Blanchard, José-Alain Sahel, Isabelle Audo

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elke RometschF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Per-Olof ThuressonF. Hoffmann-La Roche Ltd, Basel, Switzerland. per-olof.thuresson@roche.com.ORCID 0009-0008-8624-2110
Noémie HurstF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Eckhart EuleF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Isabel BachmeierF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Benoit BlanchardDHU Sight Restore, Centre Hospitalier National d'ophtalmologie des Quinze-Vingts, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423, Paris, France.
José-Alain SahelDHU Sight Restore, Centre Hospitalier National d'ophtalmologie des Quinze-Vingts, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423, Paris, France.
Isabelle AudoDHU Sight Restore, Centre Hospitalier National d'ophtalmologie des Quinze-Vingts, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423, Paris, France.

Funding

Roche Roche
6 · The paper itself

Abstract

backgroundRetinitis pigmentosa (RP) and Choroideremia (CHM) are rare inherited retinal diseases (IRDs) that can lead to severe visual impairment or blindness. Despite different underlying genetic pathways, they have many progression patterns in common, first affecting the more peripheral retina and later advancing toward the central retina. Early symptoms of both diseases include night blindness, difficulty adjusting to changing levels of light, and difficulty seeing in poor contrast. This is followed by progressive loss of the peripheral visual field in daylight, and eventually blindness. Currently, hardly any studies based on interviews that describe symptom experience and impact exist. In this concept elicitation study, we conducted qualitative interviews to identify the symptoms experienced by RP (n = 12) and CHM (n = 5) patients, and to understand the impact of symptoms on patients' lives.

resultsAmong the 14 symptoms reported, poor night vision/night blindness, difficulty seeing in bright light, and difficulty seeing in low/dim light were experienced by all participants. Over 50% of participants in either condition reported difficulty adapting from bright to dark and vice versa, poor peripheral vision, poor contrast sensitivity, poor distance vision, and poor visual acuity. Symptoms had a significant impact on activities of daily living. Most commonly impacted were the ability to navigate and the use of digital screens (n = 17/17, 100%) as well as physical functioning and work/school-related activities (n = 16/17, 94.1%). These impacts were often exacerbated by environmental factors. For instance, all participants reported this for navigation. Additionally, most participants (n = 13/17, 76.5%) reported impacts on emotional well-being. Concept saturation was shown for the RP sample (n = 12) and the combined sample (n = 17), i.e., all concepts reported were spontaneously mentioned in the first 3 sets of interviews. This suggests that further interviews would be unlikely to yield any new symptom concepts.

conclusionThe patient interviews provided insight into the patient experience of RP and CHM and formed the basis for developing a combined conceptual model of RP and CHM disease experience, suitable to serve as basis for future patient reported and performance outcome measures. Testing in larger samples, especially in CHM, is recommended to further evaluate content validity of these preliminary findings.

Indexed as

ChoroideremiaRetinitis PigmentosaAdultAgedFemaleHumansMaleMiddle AgedNight BlindnessVisual AcuityYoung AdultActivities of daily livingChoroideremiaConceptual modelDisease experienceInterviewPatient-reported outcomesQualitative researchQuality of lifeRetinitis pigmentosaSymptom burden

Identifiers

PMID40790755
PMCPMC12337473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.